Free Trial
NASDAQ:XENE

Xenon Pharmaceuticals Q2 2025 Earnings Report

Xenon Pharmaceuticals logo
$34.27 -0.13 (-0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$34.28 +0.00 (+0.01%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$1.03
Beat/Miss
N/A
One Year Ago EPS
N/A

Xenon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xenon Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Xenon Pharmaceuticals Earnings Headlines

Xenon to Report Q2 2025 Financial Results on August 11, 2025
Green Light for These Stocks
Guess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... becoming the largest shareholder in a critical mineral company tied to national security. Former hedge fund manager Whitney Tilson believes this is just the start of a sweeping plan to unlock trillions in hidden federal assets... from oil-rich land to rare earths and energy reserves. He says this could mark the beginning of the largest wealth transfer in modern U.S. history, and has identified the surprising areas where you could benefit.
Xenon to Report Q2 2025 Financial Results on August 11, 2025
See More Xenon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenon Pharmaceuticals and other key companies, straight to your email.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

View Xenon Pharmaceuticals Profile

More Earnings Resources from MarketBeat